Cargando…
4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs)
OBJECTIVES/GOALS: Non-alcoholic steatohepatitis (NASH) is a leading cause of cirrhosis in the world for which no anti-fibrotic therapies exist. We hypothesized that BMS-22 and maraviroc (MVC), chemokine receptor 2 (CCR2) and 5 (CCR5) antagonists, respectively, would diminish the fibrogenic activity...
Autores principales: | Kruger, Annie J., Bergman, Kruger, Gay, Martha, Cao, Hong, Tucker, Robin, Shivapurkar, Narayan, Smith, Jill P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823193/ http://dx.doi.org/10.1017/cts.2020.317 |
Ejemplares similares
-
4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020) -
Fate tracking reveals differences between Reelin(+) hepatic stellate cells (HSCs) and Desmin(+)
HSCs in activation, migration and proliferation
por: Chen, Ning, et al.
Publicado: (2023) -
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019) -
Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023) -
Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging
por: Li, Dan, et al.
Publicado: (2015)